Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting

Ziping Wu, Lei Zhang, Jing Peng, Shuguang Xu, Liheng Zhou, Yanpin Lin, Yan Wang, Jinglu Lu, Wenjin Yin, and Jinsong Lu

Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

ABSTRACT

Objective: Programmed death-ligand-1 (PDL1) is a molecule involved in immune evasion in various kinds of tumors. Here, we aim to determine whether the expression of PDL1 protein is related to the response of patients to neoadjuvant therapy and survival outcome.

Methods: Immunohistochemistry (IHC) was performed on paraffin-embedded tumor samples from core needle biopsy before neoadjuvant therapy (NAT). Univariate and multivariate logistic regression were used to analyze the associations between PDL1 protein expression and pathological complete response (pCR) outcome. Kaplan-Meier plot and log-rank test were used to compare disease-free survival (DFS) between groups. A Cox proportional hazards model was used to calculate the adjusted hazard ratio (HR) with 95% confidential interval (95%CI).

Results: A total of 94 patients were included for IHC testing. PDL1 protein expression on tumor cells was associated with better pCR rate in both univariate (OR = 2.621, p = 0.043) and multivariate (OR = 3.595, p = 0.029) logistic regression analysis. It was also associated with shorter DFS both by log-rank test (p = 0.015) and cox hazard model (HR = 22.824, 95%CI 1.621–321.284, p = 0.020). In hormone receptor (HR)-positive patients, PDL1 protein expression was also associated with better pCR (OR = 2.362, p = 0.022). It was also associated with poor DFS (HR = 18.821, 95%CI 1.645–215.330, p = 0.015). In hormone receptor (HR)-negative patients, PDL1 was predictive of pCR (OR = 2.621, p = 0.043) and multivariate (OR = 3.595, p = 0.029) logistic regression analysis. It was also associated with shorter DFS both by log-rank test (p = 0.015) and cox hazard model (HR = 22.824, 95%CI 1.621–321.284, p = 0.020). In hormone receptor (HR)-positive patients, PDL1 protein expression was also associated with better pCR (OR = 2.362, p = 0.022). It was also associated with poor DFS (HR = 18.821, 95%CI 1.645–215.330, p = 0.018).

Conclusions: Our results show that PDL1 protein expression is a predictive biomarker of pCR and a prognostic factor of DFS in breast cancer patients and HR-positive subgroups.

Introduction

Breast cancer is one of the most common malignancies in women worldwide. Over the years, neoadjuvant chemotherapy has become a regular procedure of breast cancer treatment. Neoadjuvant chemotherapy (NAT) was not only used for the locally advanced patients with large tumor burden, providing surgery opportunities and breast-conserving opportunities but also used to early predict the patients’ responsiveness to the treatment. Pathological complete response (pCR) refers to the status when no tumor cell residues or only ductal carcinoma in situ remains in the surgical specimens after preoperative treatment. Besides the fact that a great number of large-scale clinical trials have confirmed better survival outcomes in patients reached pCR in NAT, there were still patients not achieving pCR results in the same NAT treatment. Therefore, how to predict the patient’s response to NAT in the early stage and find out the predictive factor of pCR seem particularly important.

Programmed death-ligand-1 (PDL1), expressed on tumor cells, T cells, natural killer cells (NKs) as well as dendritic cells (DCs), is a trans-membrane glycoprotein mostly known for its critical role in tumor immune evasion. When combined with its ligand PD1, which is mainly expressed on the surface of the T cell membrane, PDL1 could induce T cell apoptosis and promote T cell differentiation towards regulatory T cells. Innate absence of PDL1 expression is associated with autoimmune diseases such as lupus. The subsequent change of PDL1 expression is often related to tumor immune evasion.

Clinically, PDL1 is associated with poorer prognosis in a variety of solid tumors, such as melanoma, renal cancer, and lung cancer. As for treatment value, antibodies of PD1/PDL1 have now been approved by the U.S. Food and Drug Administration for the clinical management of melanoma and renal cancer. However, the role of PDL1 in breast cancer oncogenesis and treatment is still quite obscure currently. The objective response rates for clinical trials of PDL1 in the treatment of breast cancer are much lower than those for melanoma. Several observational studies focused on the clinical and prognostic value of PDL1 have led to different conclusions. Many studies have reported a relatively consistent result that PDL1 represents a good survival in triple negative breast cancer (TNBC), whereas the role of PDL1 is not clear in HR-positive patients.

Two neoadjuvant clinical trials (SHPD001 and SHPD002) were conducted in our department with paclitaxel plus cisplatin weekly treatment, demonstrating a high pCR rate. Among all patients, the pCR rate was 34.4%. In human epidermal growth factor 2 (HER2) positive breast cancer and the triple negative...
breast cancer (TNBC), the pCR rate was 52.4% and 64.7%, respectively. This excellent effect is generally believed to be associated with metronomic chemotherapy and immune regulation\textsuperscript{18,19}. However, in HR-positive patients, the pCR rate is less than ideal, so we would like to find out the predictive biomarker of pCR in this part of patients to improve the therapeutic effect. Therefore, we examined the expression of PDL1 in patients from the clinical trial and explored the predictive and prognostic value of PDL1 in neoadjuvant chemotherapy in breast cancer. We hypnotized that the expression of PDL1 protein is a predictor of pCR result and survival outcome in all patients and HR-positive subgroup.

Results

Basic clinical and pathological features of patients

A total of 94 patients were provided with paraffin-embedded specimens for immunohistochemistry. Of all patients, 39% had a tumor greater than 5 cm, 41% had HER2 gene overexpression, and 50% of the patients had a ki67 expression level of more than 30%, which was consistent with the locally advanced nature of the included patients.

PDL1 was expressed on tumor cells on 50% of the breast cancer patients. Twelve percent of the patients had a positive TILS staining. Representative tissue staining was presented in Figure 1. PDL1 was expressed on 66.7% of the HER2 overexpressing breast cancer and 66.7% of the TNBC, and somehow less detected in luminal-like breast cancer (47.6%). However, no significant correlations between PDL1 expression and ER, PR, HER2 or other clinicopathological factors were found (Table 1).

Predictive value of PDL1 protein expression

Both univariate (OR = 2.621, \(p = 0.043\)) and multivariate (OR = 3.595, \(p = 0.029\)) logistic regression tests showed that positive PDL1 expression was associated with better pCR rate. At the same time, patients with high ki67 level (OR = 5.071, \(p = 0.008\)) or those with ER-negative tumors (OR = 0.110, \(p = 0.004\)) also tended to reach pCR after NAT (Table 2).

In subgroup analysis, a similar trend was observed in HR-positive patients and HER2 positive patients. In HR-positive subgroup, univariate (OR = 2.089, \(p = 0.026\)) and multivariate (OR = 2.362, \(p = 0.022\)) logistic regression test showed that positive PDL1 expression was associated with better pCR rate (Table 3). At the same time, HER2 status (OR = 4.667, \(P = 0.032\)) and ki67 status (univariate OR = 3.694, \(P = 0.018\)) was also an independent predictor of pCR. In HER2 positive subgroup, univariate (OR = 4.667, \(p = 0.032\)) and multivariate (OR = 7.979, \(p = 0.024\)) logistic regression test showed that positive PDL1 expression was associated with better pCR rate (Table 4). We failed to perform an effective subgroup analysis due to the small number of patients with TNBC breast cancer.

Figure 1. Different PDL1 immunochemistry staining levels.
A. Positive PDL1 staining on tumor cells; B. Negative PDL1 staining; C. Positive PDL1 staining on TILS (green arrow marking TILS); D. Positive PDL1 staining on tumor cells and TILS (green arrow marking TILS).
Table 1. Correlations between PD1L expression and clinicopathological factors.

| Characteristics     | PDL1 + | PDL1- | P-value |
|---------------------|--------|-------|---------|
| Age                 |        |       |         |
| <50                 | 23     | 26    | 0.536   |
| ≥50                 | 24     | 21    |         |
| Tumor size          |        |       |         |
| ≤5 cm               | 27     | 28    | 0.641   |
| >5 cm               | 20     | 17    |         |
| ER status           |        |       |         |
| Negative            | 13     | 11    | 0.636   |
| Positive            | 34     | 36    |         |
| PR status           |        |       |         |
| Negative            | 10     | 4     | 0.082   |
| Positive            | 37     | 43    |         |
| k67 status          |        |       |         |
| ≤30                 | 23     | 24    | 0.837   |
| >30                 | 24     | 23    |         |
| HER2 status         |        |       |         |
| Negative            | 26     | 29    | 0.530   |
| Positive            | 21     | 18    |         |

Table 2. Univariate and multivariate analysis for PD1L protein expression and pCR outcome.

| Age     | Univariate | Multivariate |
|---------|------------|--------------|
| N       | OR         | P-value      |
| N       | OR         | P-value      |
| <50     | 49         | 1            |
| ≥50     | 45         | 1.015        |
|         | 0.973      | 0.616        |
|         | 0.398      |              |
| Tumor size |        |              |
| ≤5 cm   | 55         | 1            |
|         | 55         | 1            |
| >5 cm   | 37         | 1.280        |
|         | 0.594      | 0.675        |
|         | 0.501      |              |
| ER status |        |              |
| Negative | 24         | 1            |
|         | 70         | 0.163        |
|         | 0.000*     | 0.110        |
|         | 0.004*     |              |
| Positive | 55         | 1            |
|         | 55         | 1            |
| Positive | 39         | 3.324        |
|         | 39         | 3.002        |
|         | 0.053      |              |
| k67 status |        |              |
| ≤30     | 47         | 1            |
|         | 47         | 1            |
| >30     | 47         | 4.233        |
|         | 47         | 5.071        |
|         | 0.008*     |              |
| PR status |        |              |
| Negative | 14         | 1            |
|         | 80         | 0.333        |
|         | 80         | 2.626        |
|         | 0.279      |              |
| Positive | 47         | 1            |
|         | 47         | 1            |
| Positive | 47         | 2.621        |
|         | 47         | 3.595        |
|         | 0.029*     |              |

Table 3. Predictive value of PD1L expression in HR-positive BC.

| Clinicopathological factors | Univariate | Multivariate |
|-----------------------------|------------|--------------|
| OR             | P-value   | OR           | P-value |
| Age             |            |              |
| <50             | 1          | 1            |
| ≥50             | 0.873      | 0.792        |
|                 | 0.965      | 0.951        |
| Tumor size      |            |              |
| ≤5 cm           | 1          | 1            |
|                 | 1.227      | 0.694        |
|                 | 0.976      | 0.967        |
| HER2            |            |              |
| Negative        | 1          | 2.929        |
|                 | 0.042*     | 3.226        |
|                 | 0.045*     |              |
| Positive        | 1          | 3.694        |
|                 | 0.018*     | 4.669        |
|                 | 0.015*     |              |
| k67 status      |            |              |
| ≤30             | 1          | 1            |
|                 | 1          | 1            |
| >30             | 1          | 3.694        |
|                 | 0.018*     | 4.669        |
|                 | 0.015*     |              |
| PD-L1           |            |              |
| Negative        | 1          | 2.089        |
|                 | 0.026*     | 2.365        |
|                 | 0.022*     |              |

Table 4. Predictive value of PD1L expression in HER2 positive BC.

| Clinicopathological factors | Univariate | Multivariate |
|-----------------------------|------------|--------------|
| OR             | P-value   | OR           | P-value |
| Age             |            |              |
| <50             | 1          | 1            |
| ≥50             | 2.86       | 0.124        |
|                 | 1.388      | 0.699        |
| Tumor size      |            |              |
| ≤5 cm           | 1          | 1            |
|                 | 1.750      | 0.402        |
|                 | 0.726      | 0.713        |
| >5 cm           | 1          | 1            |
|                 | 0.278      | 0.072        |
|                 | 0.210      | 0.089        |
| HER2            |            |              |
| Negative        | 1          | 1            |
| Positive        | 3.422      | 0.074        |
|                 | 5.776      | 0.052        |
| k67 status      |            |              |
| ≤30             | 1          | 1            |
|                 | 1.373      | 0.694        |
|                 | 0.976      | 0.967        |
| >30             | 1          | 1            |
|                 | 4.669      | 0.018*       |
|                 | 4.669      | 0.015*       |
| PD-L1           |            |              |
| Negative        | 1          | 4.667        |
| Positive        |            | 4.667        |
|                 | 0.032*     | 7.979        |
|                 | 0.024*     |              |

**Prognostic value of PD1L protein expression**

With the median follow up time of 27 months, six events occurred in PDL1 positive patients and one event occurred in PDL1 negative patients. Kaplan-Meier plot showed that PDL1-negative patients yielded better survival than PDL1-positive counterparts (Log-rank p = 0.015; Figure 2A). Cox hazard model also showed that patients without PDL1 expression (HR = 22.824, p = 0.020, 95%CI 1.621–321.284) survived better (Table 5). The patient’s age (HR = 0.123, p = 0.050, 95%CI 0.015–0.999), and postoperative lymph node status (HR = 37.897, p = 0.003, 95%CI 3.391–423.536) were also independent prognostic factors of DFS.

In subgroup analysis, a similar trend was observed in HR-positive patients. Kaplan-Meier plot showed that PDL1-positive patients had poorer survival than the PDL1-negative patients (Log-rank p = 0.020; Figure 2B). Cox hazard model also suggested a higher risk of recurrence in the PDL1-positive group (HR = 18.821, p = 0.018; Table 6). The prediction value of PDL1 was not observed in HER2-positive BC (Log-rank p = 0.056; Figure 2C). We failed to perform an effective subgroup analysis due to the small number of patients with TNBC breast cancer.

**Discussion**

PD1L gene is well known in cancer immunology. Compared to other types of cancer, the role of PD1L is relatively ambiguous in breast cancer, especially in HR-positive breast cancer. Our study showed that PD1L is a predictive factor of response to NAT and long-term survival in breast cancer patients and HR-positive subtype as well. As far as we know, this is the first time that the predictive and prognostic value of PD1L protein was reported in HR-positive breast cancer patients.

According to our results, patients with PD1L protein expression are more likely to reach pCR in all populations and in HR-positive BC populations, but at the same time are more susceptible to recurrence.

Regarding the predictive value of PD1L in neoadjuvant chemotherapy, our results were basically consistent with other researchers. Wimberly found in a small sample study that the immunofluorescence expression of PD1L in breast cancer was associated with pCR in patients; Bertucci had...
detected PDL1 mRNA expression in inflammatory breast cancer patients and found that PDL1 mRNA up-regulation was associated with pCR; Sabatier\textsuperscript{22} used DNA microarray technology to analyze breast cancer tissue and found that patients with high expression of PDL1 mRNA in the general population were likely to achieve pCR, but the study did not find the predictive value of PDL1 mRNA expression in ER-positive breast cancer.

For the first time, our study observed the predictive effect of PDL1 expression on pCR in HR-positive breast cancer subpopulations. Hormone receptor-positive breast cancer are a bunch of breast cancer characterized by slow disease progression and relatively good prognosis. However, this subtype of breast cancer is also known for its insensitivity to chemotherapy. Thus, PDL1 could be used to predict pCR in HR-positive breast cancer to avoid unnecessary NAT.

The prognostic value of PDL1 is quite different in each study. Studies from Li\textsuperscript{13}, Beckers\textsuperscript{14}, and Sabatier\textsuperscript{22} showed that PDL1 protein expression or mRNA up-regulation in TNBC or Basal-like breast cancer represented a good prognosis. But in Chen’s study, residual PDL1 expression in patients after neoadjuvant chemotherapy was associated with poor long-term survival. One explanation is that the residual tumor tissues tended to be luminal subtype because TNBC is known more sensitive to NAT. This is consistent with our findings that HR-positive breast cancer with PDL1 protein

---

**Table 5.** Multivariable analyses of associations between clinicopathological factors and disease-free survival in all patients.

| Clinicopathological factors | Disease-free survival |
|-----------------------------|-----------------------|
|                            | HR | 95%CI       | P value |
| PDL1 Negative               | 1  |            |         |
| Positive                    | 22.824 | 1.621–321.284 | 0.020*  |
| Age                         | 0.123 | 0.015–0.999  | 0.050*  |
| ≤50                         | 1  |            |         |
| >50                         | 5.602 | 0.967–32.449 | 0.055   |
| Tumor size                  | 1  |            |         |
| ≤5                          | 0.496 | 0.043–5.784  | 0.576   |
| >5                          | 1  |            |         |
| ER Negative                 | 2.875 | 0.428–19.325 | 0.277   |
| Positive                    | 1  |            |         |
| HER2 status                 | 1.471 | 0.487–14.706 | 0.264   |
| Negative                    | 1  |            |         |
| Positive                    | 0.266 | 0.018–3.933  | 0.335   |
| ki67 status                 | 1  |            |         |
| ≤30                         | 37.897 | 3.391–423.536 | 0.003*  |
| >30                         | 1  |            |         |
| PR Negative                 | 0.266 | 0.018–3.933  | 0.335   |
| Positive                    | 1  |            |         |
| ypLN Negative               | 1  |            |         |
| Positive                    | 48.649 | 2.973–796.003 | 0.006*  |

a: p < 0.05 considering statistical significant.

**Table 6.** Prognostic value of PDL1 expression in HR-positive BC.

| Clinicopathological factors | Disease-free survival |
|-----------------------------|-----------------------|
|                            | HR | 95%CI       | P value |
| PDL1 Negative               | 1  |            |         |
| Positive                    | 18.821 | 1.645–215.330 | 0.018*  |
| Age                         | 0.256 | 0.041–1.606  | 0.146   |
| ≤50                         | 1  |            |         |
| >50                         | 10.047 | 1.115–90.555 | 0.040*  |
| Tumor size                  | 1  |            |         |
| ≤5                          | 2.654 | 0.703–42.968 | 0.284   |
| >5                          | 4.140 | 0.575–29.841 | 0.159   |
| HER2 status                 | 1  |            |         |
| Negative                    | 0.266 | 0.018–3.933  | 0.335   |
| Positive                    | 1  |            |         |
| ki67 status                 | 1  |            |         |
| ≤30                         | 48.649 | 2.973–796.003 | 0.006*  |
| >30                         | 1  |            |         |
| PR Negative                 | 1  |            |         |
| Positive                    | 48.649 | 2.973–796.003 | 0.006*  |

a: p < 0.05 considering statistical significant.
expression is prone to disease recurrence. Our findings are also supported by Muenst’s results, in which luminal-B patients had a poorer survival with PDL1 expression. Thus, we hypothesize that the prognostic value of PDL1 in breast cancer patients is dependent on different breast cancer subtypes. Different constituent ratios of breast cancer subtypes in each study are likely to affect the final conclusion.

Of note, PDL1—as a molecule that involved in tumor immune escape—is thought to indicate a poor overall survival in many tumors. The mechanism is generally thought to be related to a PDL1-mediated T-killer cell apoptosis and T-regulatory cell differentiation. Nevertheless, laboratory experiments showed that chemotherapy could induce the expression of PDL1 and other immune escape-associated molecules (CD47, CD73, etc.) in breast cancer cells, leading to inactivation of T effector cells. Therefore, these tumor cells that survived chemotheraphy will have a higher immune escape capacity, leading to long-term recurrence and metastasis of the disease. This might explain the result from our study that patients with PDL1 protein expression tended to receive pCR result but were more likely to suffer disease relapse.

Relatively small sample size is clearly one main deficit of our study, resulting in the failure to perform subgroup analyzes in TNBC and HER2 positive breast cancer. And due to the short follow-up period, the OS analysis cannot be carried out yet, pending further follow up.

In conclusion, our research demonstrates that PDL1 protein expression is a predictive factor of pCR result from neoadjuvant therapy and DFS in breast cancer patients and HR-positive subtypes.

Methods & materials

Patients and specimen

BC patients from two paclitaxel- and cisplatin-based neoadjuvant clinical trials were included. The two trials were separately registered in ClinicalTrials.gov as SHPD001 (NCT02199418) and SHPD002 (NCT02221999).

Women aged ≥18 years old with histologically confirmed locally advanced invasive breast cancer were included. For all patients, Paclitaxel 80 mg/m² was given weekly starting on day 1 for 16 weeks; Cisplatin 25 mg/m² was given weekly on days 1, 8, and 15 every 28 days for four cycles. For HER2 positive patients in SHPD001, trastuzumab was recommended concurrently. All HER2 positive patients in SHPD002 received concurrent trastuzumab. For hormone receptor positive patients in SHPD002, endocrine therapy of aromatase inhibitor or gonadotropin-releasing hormone agonist was randomized together with chemotherapy according to their menstrual status. Planned surgery was given sequentially after neoadjuvant chemotherapy.

The tissue sample was collected at core needle biopsy before any treatment. Patients’ information was collected at core needle biopsy, including patient’s age, menstrual status, family history, size of the preoperative primary tumor, estrogen and progesterone receptor status of the puncture specimen, HER-2 receptor status of the puncture specimen, and PCR status after NAT. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Both clinical trials have been approved by the Ethics Committee of Renji hospital. All patients provided with informed consents.

Immunohistochemistry (IHC)

Estrogen receptor (ER), progesterone receptor (PR), ki67, HER2, and PDL1 were performed on paraffin-embedded tumor samples from biopsy. ER, PR, HER2, ki67 was detected using rabbit monoclonal antibodies SP1, EE2, 4B5 (F. Hoffmann-La Roche Ltd.), MIBI (Leica Biosystems Newcastle Ltd.). PDL1 was detected using the rabbit anti-PDL1 monoclonal antibody E1L3N (Cell Signaling Technology, INC.).

ER and PR positive was defined as more than 1% of positive nuclear staining, ki67 level was recorded as a continuous value. HER2 assessment was conducted according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) recommendations. PDL1 expression was assessed according to clinical trial criteria with minor modulation: membranous and cytoplasmic staining of tumor cell was counted for PDL1 tumor assessment; cytoplasmic staining of the tumor infiltrating lymphocytes (TILS) was counted for PDL1 stromal assessment. PDL1 positive was specified as more than 1% of positive staining on the tumor cell. TILS positive was defined as more than 1% of the positive staining on TILS.

Statistical analysis

Correlations between PDL1 protein expression and other clinicopathological characteristics were tested using the chi-squared test. Univariate and multivariate logistic regression tests were used to analyze the associations between PDL1 expression and pCR outcome. Disease-free survival (DFS) was used for survival analysis. DFS was defined as the time from surgery to the first disease relapse including one of the following events: a distant disease metastasis, recurrence of ipsilateral locoregional invasive disease, contralateral breast cancer or death. Survival curve was derived from Kaplan–Meier method; the log-rank test was used to compare survival difference. Cox proportional hazards model was used to calculate the adjusted hazard ratio (HR) with 95% confidential interval (CI). Patient age, tumor size, ER, PR, HER2, and ki67 were adjusted. Statistical results were considered significant with a P value <0.05. All statistical analysis was carried out using STATA statistics SE 14 (Stata Corp LP, College Station, TX). Kaplan-Meier plot was drawn in SPSS statistics version 23 (SPSS, Inc., Chicago, IL, USA).

Disclosure of potential conflicts of interests

No potential conflicts of interest were disclosed.

Funding

This work is supported by grants from the National Natural Science Foundation of China [grant numbers 81172505], the Shanghai Natural Science Foundation of China [grant numbers 81172505], the Shanghai Natural Science Foundation of China [grant numbers 81172505], the Shanghai Natural Science Foundation of China [grant numbers 81172505].
References

1. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012;366(26):2438–2441. doi:10.1056/NEJMmp1205737. PubMed PMID: 2246508.

2. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTENeoBC pooled analysis. Lancet (London, England). 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8. PubMed PMID: 24529560.

3. Cortazar P, Geyer CE Jr. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441–1446. doi:10.1245/s10434-015-4404-8. PubMed PMID: 25727556.

4. Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Iluch A, Staroslawska E, de la Haba-Rodriguez J, Im S-A, Pedrini JL, et al. 5-year analysis of neoadjuvant pertuzumab and taxtuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. Epub 2016/ 05/18. doi:10.1016/s1470-2045(16)00163-7. PubMed PMID: 27179402.

5. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Oncol Rep. 2016;27(3):409–416. Epub 2015/ 12/19. doi:10.3892/or.2015.4155. PubMed PMID: 26681673.

6. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Overexpression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28(3):682–688. Epub 2010/ 04/08. doi:10.1007/s12032-010-9515-2. PubMed PMID: 20373055.

7. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–3385. Epub 2006/04/06. doi:10.1158/0008-5472.can-05-4303. PubMed PMID: 16585157.

8. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baronie G, Nassin R, Minocci D, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol. 2014;25(12):2433–2442. doi:10.1093/annonc/mdu252. PubMed PMID: 25223485.

9. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757–1766. Epub 2010/02/10. doi:10.1002/cncr.24899. PubMed PMID: 20143437.

10. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li B-Z, Shi Y-H, Xiao Y-S, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971–979. doi:10.1186/1756-4791-3-971. PubMed PMID: 19188168.

11. Hamaishi J, Mandal D, Iwasaki M, Okazaki T, Tamakita Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–3365. doi:10.1073/pnas.0611533104. PubMed PMID: 17360651; PubMed Central PMCID: PMCPMC1805580.

12. Li X, Wetherilt CS, Krishnamurti U, Yang J, Ma Y, Styblo TM, Meisel JL, Peng L, Siddiqui MT, Cohen C, et al. Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer. Am J Clin Pathol. 2016;146(4):496–502. Epub 2016/10/01. doi:10.1093/ajcp/aqw134. PubMed PMID: 27686176.

13. Beckers RK, Selinger CI, Vilain R, Madore J, Wilmott JS, Harvey K, Holliday A, Cooper CL, Robbins E, Gillett D, et al. PD-L1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016;69(1):25–34. doi:10.1111/his.12904. PubMed PMID: 26586661.

14. Ali HR, Glont SE, Bloys FM, Provenzano E, Dawson SJ, Liu B, Hiller L, Dunn J, Poole CJ, Rowden S, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26(7):1488–1493. Epub 2015/04/22. doi:10.1093/annonc/mdv192. PubMed PMID: 25897014.

15. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773–2782. Epub 2014/03/22. doi:10.1158/1078-0432.ccr-13-2702. PubMed PMID: 24647569.

16. Zhou L, Xu S, Yin W, Lin Y, Du Y, Jiang Y, Wang Y, Zhang J, Wu Z, Lu J. Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase I study. Oncotarget. 2017;8(45):79305–79314. Epub 2017/11/08. doi:10.18632/oncotarget.17954. PubMed PMID: 29108309; PubMed Central PMCID: PMCPMC5668042.

17. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitovog L, Chaffuert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641–648. Epub 2006/09/09. doi:10.1007/s00262-006-0225-8. PubMed PMID: 16960692.

18. Demaria S, Volin MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001;7(10):3025–3030. Epub 2001/02/13. PubMed PMID: 11595609.

19. Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Rimm DL. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015;3(4):326–332. doi:10.1158/2326-6066.cIR-14-0133. PubMed PMID: 25527356; PubMed Central PMCID: PMCPMC4390454.

20. Bertucci F, Finetti P, Colpaert C, Mammessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S. PD-L1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 2015;6(15):13506–13519. doi:10.18632/oncotarget.3642. PubMed PMID: 25940795; PubMed Central PMCID: PMCPMC4537030.

21. Sabatier R, Finetti P, Mammessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PD-L1 expression in breast cancer. Oncotarget. 2015;6(7):5449–5464. Epub 2015/02/12. doi:10.18632/oncotarget.3216. PubMed PMID: 25669979; PubMed Central PMCID: PMCPMC4467160.
23. Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, Pan F, Semenza GL. Chemotherapy induces enrichment of CD47 (+)/CD73(+)/PDL1(+) immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci U S A. 2018;115:E1239–E1248. doi:10.1073/pnas.1718197115. PubMed PMID: 29367423.

24. Zhang P, Su DM, Liang M, Fu J. Chemopreventive agents induce programmed death-1 ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008;45(5):1470–1476. doi:10.1016/j.molimm.2007.08.013. PubMed PMID: 17920123.

25. Qin X, Liu C, Zhou Y, Wang G. Cisplatin induces programmed death-1 ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk/MAPK signaling pathway. Cell Mol Biol (Noisy-Le-Grand). 2010;56 Suppl:Ol1366–72. Epub 2010/10/22. PubMed PMID: 20937224.

26. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of clinical oncology/College of American pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–256. Epub 2013/10/09. doi:10.5858/arpa.2013-0953-SA. PubMed PMID: 24099077; PubMed Central PMCID: PMCPMC4086638.

27. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–2467. Epub 2016/05/04. doi:10.1200/jco.2015.64.8931. PubMed PMID: 27138582.